Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease

Abstract 

Previous studies have suggested that quetiapine, an atypical antipsychotic drug, may have beneficial effects on cognitive impairment, and be a neuroprotectant in treating neurodegenerative diseases. In the present study, we investigated the effects of quetiapine on memory impairment and pathological changes in an amyloid precursor protein (APP)/presenilin-1 (PS-1) double transgenic mouse model of Alzheimer's disease (AD). Non-transgenic and transgenic mice were treated with quetiapine (0, 2.5, or 5mg/(kgday)) for 1, 4, and 7 months in drinking water from the age of 2 months. After 4 and 7 months of continuous quetiapine administration, memory impairment was prevented, and the number of β-amyloid (Aβ) plaques decreased in the cortex and hippocampus of the transgenic mice. Quetiapine also decreased brain Aβ peptides, β-secretase activity and expression, and the level of C99 (an APP C-terminal fragment following cleavage by β-secretase) in the transgenic mice. Furthermore, quetiapine attenuated anxiety-like behavior, up-regulated cerebral Bcl-2 protein, and decreased cerebral nitrotyrosine in the transgenic mice. These findings suggest that quetiapine can alleviate cognitive impairment and pathological changes in an APP/PS1 double transgenic mouse model of AD, and further indicate that quetiapine may have preventive effects in the treatment of AD.

Keywords: Quetiapine, APP/PS1 double transgenic mouse model, Alzheimer's disease, Memory, Plaque, β-Amyloid, β-Secretase